started · updated
Hims & Hers and Noom launch new peptide treatment services
Telehealth companies Hims & Hers and Noom have announced the launch of peptide-based treatment services, marking a significant expansion of the direct-to-consumer wellness market. Hims & Hers introduced its Peptides+ platform, which offers five initial treatments: Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine. These products are provided through licensed U.S. compounding pharmacies.
While these treatments are intended to support areas such as muscle growth, energy production, and anti-aging, the company acknowledged that more research is needed regarding their efficacy. Most of these compounded peptides have not been approved by the Food and Drug Administration (FDA) and lack randomized controlled trials to confirm safety and efficacy in humans.
The move follows a shift in federal oversight, as the Department of Health and Human Services has highlighted these drugs. Despite the service launch, Hims & Hers stock saw a decline of approximately 2.93 percent during trading.
Entities
Department of Health and Human Services · Food and Drug Administration · Hims & Hers Health, Inc. · Noom · United States